Imatinib: The narrow line between immune tolerance and activation

Trends in Molecular Medicine

Volumn 11, Issue 9, 2005, Pages 397-402

  Mohty, Mohamad ^a,b   Blaise, Didier ^a,b,c   Olive, Daniel ^a,b,c   Gaugler, Béatrice ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

BONE MARROW CELL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GASTROINTESTINAL STROMAL TUMOR; GENE TARGETING; GENE TRANSLOCATION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NONHUMAN; REVIEW; STEM CELL; TUMOR IMMUNITY; VACCINATION;

EID: 24344507209     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.07.007     Document Type: Article

References (47)

1. F. Cheng A critical role for Stat3 signaling in immune tolerance Immunity 19 2003 425 436
2. Q. Lu, and G. Lemke Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family Science 293 2001 306 311
3. D.H. Munn Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase Science 297 2002 1867 1870
4. J. Banchereau Dendritic cells: controllers of the immune system and a new promise for immunotherapy Ann. N. Y. Acad. Sci. 987 2003 180 187
5. A. Lanzavecchia Immunology. Licence to kill Nature 393 1998 413 414
6. A. Langenkamp Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells Nat. Immunol. 1 2000 311 316
7. A.J. Muller BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias Mol. Cell. Biol. 11 1991 1785 1792
8. M.W. Deininger The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
9. T.G. Lugo Tyrosine kinase activity and transformation potency of bcr-abl oncogene products Science 247 1990 1079 1082
10. M.W. Deininger The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells Blood 90 1997 3691 3698
11. B.J. Druker Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042
12. H.M. Kantarjian Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha Blood 104 2004 1979 1988
13. M.C. Heinrich Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J. Clin. Oncol. 20 2002 1692 1703
14. E. Buchdunger Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class Proc. Natl. Acad. Sci. U. S. A. 92 1995 2558 2562
15. M. Mohty, and B. Gaugler Dendritic cells: interfaces with immunobiology and medicine. A report from the Keystone Symposia Meeting held in Keystone, 3-8 March 2003 Leukemia 17 2003 1753 1758
16. M. Mohty Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts Leukemia 16 2002 2197 2204
17. F. Baron Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J. Clin. Oncol. 23 2005 1993 2003
18. D.M. Pardoll Cancer vaccines Nat. Med. 4 5 Suppl. 1998 525 531
19. J. Banchereau Immunobiology of dendritic cells Annu. Rev. Immunol. 18 2000 767 811
20. J.M. Aswald Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia Cytokines Cell. Mol. Ther. 7 2002 143 149
21. Y. Zeng Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia Int. J. Cancer 110 2004 251 259
22. H. Wang Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance Blood 105 2005 1135 1143
23. M. Bocchia Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial Lancet 365 2005 657 662
24. Z. Li Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia Clin. Cancer Res. 11 2005 4460 4468
25. C. Castelli Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer Cancer Immunol. Immunother. 53 2004 227 233
26. N. Sato The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia Hematol. Oncol. 21 2003 67 75
27. L. Wang Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib Leukemia 18 2004 1025 1027
28. M. Mohty Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia Blood 103 2004 4666 4668
29. C. Borg Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects J. Clin. Invest. 114 2004 379 388
30. J. Cools A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N. Engl. J. Med. 348 2003 1201 1214
31. S. Appel Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells Blood 103 2004 538 544
32. S. Appel Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways Clin. Cancer Res. 11 2005 1928 1940
33. A.L. Dewar Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors Leukemia 17 2003 1713 1721
34. A.L. Dewar Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood 105 2005 3127 3132
35. A.B. Dietz Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo Blood 104 2004 1094 1099
36. K. Cwynarski Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro Leukemia 18 2004 1332 1339
37. R. Seggewiss Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood 105 2005 2473 2479
38. Taieb, J. et al. (2004) Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103, 1966-1967; author reply 1967
39. N. Boissel Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate Leukemia 18 2004 1656 1661
40. D.I. Gabrilovich Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat. Med. 2 1996 1096 1103
41. J.J. Molldrem Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions Curr. Opin. Hematol. 9 2002 503 508
42. J.J. Molldrem Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nat. Med. 6 2000 1018 1023
43. A. Burchert Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia Blood 101 2003 259 264
44. M. Deininger The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2005 2640 2653
45. G.N. Mattiuzzi Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate Clin. Cancer Res. 9 2003 976 980
46. A.M. Tsimberidou Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature Leuk. Res. 28 2004 657 660
47. A.L. Dewar Imatinib inhibits the functional capacity of cultured human monocytes Immunol. Cell Biol. 83 2005 48 56